Gothenburg, Sweden, June 23, 2016 – Immunicum AB (publ), pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced preliminary plans to conduct two separate studies with INTUVAX for the treatment of advanced melanoma in combination with immune checkpoint inhibitors, one in first line treatment, the other one as second line treatment, in the U.S. and Sweden respectively.
Currently, the Company’s intention is to carry out two separate clinical trials with INTUVAX for the treatment of melanoma in combination with different immune checkpoint inhibitors that together will provide complementary data. The preliminary plans for the implementation of the melanoma studies are still subject to change, based mainly on the authorities’ response after the submitted applications for starting the clinical trials. The Company will provide further updates as the plans progress.
For further information, please contact:
Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
The Company’s Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se
INTUVAX is a cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated white blood cells, so called dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient’s cytotoxic T lymphocytes.
About Immunicum AB (publ)
Immunicum AB (publ) is working to develop and advance cancer immune primers for the treatment of tumor diseases. A clinical phase II trial for the Company’s most advanced product – INTUVAX® against kidney cancer – has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST).
For more information, please visit www.immunicum.com